eamdacademy.org-1158-1792280467-d506101446 1792280467 Eurasian Academy of Medicine and Dentistry info@eamdacademy.org Eurasian Academy of Medicine and Dentistry Journal of Applied Pharmaceutical Technologies and Systems J Appl Pharm Technol Syst 3149-9589 2026 5 2 Peter Novak Jana Svoboda 2026 10.68159/d506101446 https://eamdacademy.org/pub/journal/3/article/d506101446 Lawrence XY, Kopcha M. The future of pharmaceutical quality and the path to get there. Int J Pharm. 2017;528(1-2):354-9. Zhang L, Mao S. Application of quality by design in the current drug development. Asian J Pharm Sci. 2017;12(1):1-8. Sangshetti JN, Deshpande M, Zaheer Z, Shinde DB, Arote R. Quality by design approach: Regulatory need. Arab J Chem. 2017;10(Suppl):S3412-25. Buttini F, Rozou S, Rossi A, Zoumpliou V, Rekkas DM. The application of Quality by Design framework in the pharmaceutical development of dry powder inhalers. Eur J Pharm Sci. 2018;113:64-76. Nejadnik MR, Randolph TW, Volkin DB, Schöneich C, Carpenter JF, Crommelin DJ, et al. Postproduction handling and administration of protein pharmaceuticals and potential instability issues. J Pharm Sci. 2018;107(8):2013-9. Almaya A, De Belder L, Meyer R, Nagapudi K, Lin HR, Leavesley I, et al. Control strategies for drug product continuous direct compression—state of control, product collection strategies, and startup/shutdown operations for the production of clinical trial materials and commercial products. J Pharm Sci. 2017;106(4):930-43. Nasr MM, Krumme M, Matsuda Y, Trout BL, Badman C, Mascia S, et al. Regulatory perspectives on continuous pharmaceutical manufacturing: moving from theory to practice: September 26-27, 2016, international symposium on the continuous manufacturing of pharmaceuticals. J Pharm Sci. 2017;106(11):3199-206. Arana C, Ji J, Krug E, Liu J, McCaig L, Rozaieski B, et al. Industry perspective on temperature cycling studies to meet regulatory temperature excursion support requirements: survey outcome and recommendations. J Pharm Sci. 2023;112(12):2981-90. Siska C, Harber P, Kerwin BA. Shocking data on parcel shipments of protein solutions. J Pharm Sci. 2020;109(1):690-5. Jiskoot W, Nejadnik MR, Sediq AS. Potential issues with the handling of biologicals in a hospital. J Pharm Sci. 2017;106(6):1688-9. Linkuvienė V, Ross EL, Crawford L, Weiser SE, Man D, Kay S, et al. Effects of transportation of IV bags containing protein formulations via hospital pneumatic tube system: particle characterization by multiple methods. J Pharm Sci. 2022;111(4):1024-39. Susam MM, Sikking C, Hardebol L, Florack M, Crul M. Shock and Temperature Monitoring During Transport of Immunoglobulins from a Hospital to Patients' Homes: A Pilot Study. J Pharm Sci. 2024;113(8):2268-73. Blümel M, Liu J, de Jong I, Weiser S, Fast J, Litowski J, et al. Current industry best practice on in-use stability and compatibility studies for biological products. J Pharm Sci. 2023;112(9):2332-46. Kamen DE, Crotts G, Narasimhan C, Hu Q, Bhargava AC, Muthurania K, et al. An intercompany perspective on compatibility and in-use stability studies to enable administration of biopharmaceutical drug products. J Pharm Sci. 2022;111(4):1092-103. Tian G, Koolivand A, Arden NS, Lee S, O'Connor TF. Quality risk assessment and mitigation of pharmaceutical continuous manufacturing using flowsheet modeling approach. Comput Chem Eng. 2019;129:106508. Stauffer F, Vanhoorne V, Pilcer G, Chavez PF, Schubert MA, Aerts L, et al. Raw material variability of an active pharmaceutical ingredient and its relevance for processability in secondary continuous pharmaceutical manufacturing. Eur J Pharm Biopharm. 2018;127:92-103. Stauffer F, Vanhoorne V, Pilcer G, Chavez PF, Schubert MA, Vervaet C, et al. Managing active pharmaceutical ingredient raw material variability during twin-screw blend feeding. Eur J Pharm Biopharm. 2019;135:49-60. Stauffer F, Vanhoorne V, Pilcer G, Chavez PF, Vervaet C, De Beer T. Managing API raw material variability during continuous twin-screw wet granulation. Int J Pharm. 2019;561:265-73. Stauffer F, Vanhoorne V, Pilcer G, Chavez PF, Vervaet C, De Beer T. Managing API raw material variability in a continuous manufacturing line–Prediction of process robustness. Int J Pharm. 2019;569:118525. Burcham CL, Florence AJ, Johnson MD. Continuous manufacturing in pharmaceutical process development and manufacturing. Annu Rev Chem Biomol Eng. 2018;9(1):253-81. Vanhoorne V, Vervaet C. Recent progress in continuous manufacturing of oral solid dosage forms. Int J Pharm. 2020;579:119194. Mason BD, Lowe K, Dong J, Salamat-Miller N. A practical tool for risk-based in-use compatibility assessments. J Pharm Sci. 2023;112(11):2938-46. Sreedhara A, Zamiri C, Goswami S, Weiser S, Cram M, Christian TR, et al. Challenges of using closed system transfer devices with biological drug products: an industry perspective. J Pharm Sci. 2020;109(1):22-9. Besheer A, Burton L, Galas RJ Jr, Gokhale K, Goldbach P, Hu Q, et al. An industry perspective on compatibility assessment of closed system drug-transfer devices for biologics. J Pharm Sci. 2021;110(2):610-4. Patke S, Gaillat EN, Calero-Rubio C, Gooding TB, Audat H, Leman M, et al. A systematic approach to evaluating closed system drug-transfer devices during drug product development. J Pharm Sci. 2022;111(5):1325-34. van den Berg R, Penning R, Nejadnik R, Jiskoot W, Menzen T, Mastrobattista E. Quality (Attributes) over quantity: Minimal essential quality attributes for determining antibody stability in postproduction handling stability studies. J Pharm Sci. 2025;104011. Fast J, Christian T, Crul M, Jiskoot W, Nejadnik MR, Medina A, et al. Use of Closed System Transfer Devices (CSTDs) with protein-based therapeutic drugs—a non-solution for a non-problem? J Pharm Sci. 2024;113(2):298-305. Sampathkumar K, Kerwin BA. Roadmap for drug product development and manufacturing of biologics. J Pharm Sci. 2024;113(2):314-31.